WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising:

   (a) mycophenolic acid or a pharmaceutically acceptable salt thereof;

   (b) a betamethasone at a concentration of 0.01 % w/w to 0.5 % w/w; and

   (c) a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1, wherein elements 1a) and 1b) are the sole active ingredients in the pharmaceutical composition.

3. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable salt of mycophenolic acid is mycophenolate sodium.

4. The pharmaceutical composition of claim 1, wherein the betamethasone is selected from the group consisting of betamethasone acetate, betamethasone sodium phosphate, betamethasone valerate, and betamethasone dipropionate.

5. The pharmaceutical composition of claim 4, wherein the betamethasone is betamethasone sodium phosphate.

6. The pharmaceutical composition of claim 5, wherein elements 1a) and 1b) are the sole active ingredients in the pharmaceutical composition

7. The pharmaceutical composition of claim 5, further comprising chondroitin sulfate.

8. The pharmaceutical composition of claim 7, wherein elements 1a), 1b) and the chondroitin sulfate are the sole active ingredients in the pharmaceutical composition.

9. The pharmaceutical composition of claim 1, wherein the mycophenolic acid is present at a concentration of 0.05 % w/w to 1.0 % w/w.

10. The pharmaceutical composition of claim 9, wherein the mycophenolic acid is present at a concentration of 0.08% w/w to 0.8% w/w.

11. The pharmaceutical composition of claim 10, wherein the mycophenolic acid is present at a concentration of 0.1% w/w to 0.6% w/w/.

12. The pharmaceutical composition of claim 1, wherein the betamethasone is betamethasone sodium phosphate and is present at a concentration of 0.008% w/w to 0.05% w/w.

13. The pharmaceutical composition of claim 1 formulated as eye drops.

14. Use of the pharmaceutical of claim 1 for use in the preparation of a medicament for the treatment of an ocular surface disease.

15. The use of claim 13, wherein the ocular surface disease is selected from the group consisting of keratoconjunctivitis sicca, episodic dry eye disease, recalcitrant dry eye disease, age-related dry eye, neurotrophic ocular surface disease, meibomian gland disease and blepharitis.